Kaliumfosfaat B. Braun

Dipotassium Phosphate, the active ingredient in Kaliumfosfaat B. Braun, is an electrolyte presented as an injection solution for intravenous use. It treats hypophosphatemia, hypokalemia and provides electrolyte replacement in patients requiring correction of potassium and phosphate deficits.

GNH USA supplies Kaliumfosfaat B. Braun as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Kaliumfosfaat B. Braun is used in the management of electrolyte disorders, particularly those involving phosphate and potassium deficits. - Hypophosphatemia: restores serum phosphate levels and supports cellular energy metabolism. - Hypokalemia: supplies potassium ions to correct low serum potassium and prevent cardiac arrhythmias. - Electrolyte replacement therapy: provides combined potassium and phosphate ions for patients undergoing surgery, trauma or renal replacement therapy.

Kaliumfosfaat B. Braun may be associated with adverse reactions following intravenous administration.

Common Side Effects: - Local irritation at the infusion site. - Mild nausea or vomiting. - Transient headache. - Mild hyperkalemia (elevated serum potassium). - Mild hyperphosphatemia (elevated serum phosphate).

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Severe hyperphosphatemia causing calcium-phosphate precipitation. - Allergic reactions including rash, urticaria, or anaphylaxis. - Metabolic acidosis. - Vascular thrombosis at the infusion site.

When using Kaliumfosfaat B. Braun, clinicians should consider several safety measures. - Renal function: assess kidney function before administration, as impaired excretion can exacerbate hyperkalemia. - Cardiac status: monitor ECG in patients with existing cardiac disease or electrolyte disturbances. - Serum electrolytes: check baseline potassium and phosphate levels and re‑measure after infusion. - Infusion rate: administer at the prescribed rate to avoid rapid shifts in serum concentrations. - Compatibility: verify compatibility with other IV solutions before mixing. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kaliumfosfaat B. Braun can interact with other medications that affect electrolyte balance or cardiac conduction.

Major Interactions (Avoid): - ACE inhibitors or ARBs: may potentiate hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of severe hyperkalemia. - Sodium bicarbonate: can precipitate calcium phosphate when combined.

Moderate Interactions (Monitor Closely): - Digoxin: altered potassium levels can affect digoxin toxicity. - Calcium channel blockers: monitor for additive cardiac effects. - Insulin or beta‑agonists: may shift potassium intracellularly, requiring electrolyte monitoring.